Attached files
| file | filename |
|---|---|
| 8-K - 8-K - Aeglea BioTherapeutics, Inc. | d147883d8k.htm |
| EX-99.1 - EX-99.1 - Aeglea BioTherapeutics, Inc. | d147883dex991.htm |
Exhibit 99.2
Aeglea BioTherapeutics to Present New Data at
American Association for Cancer Research (AACR) Annual Meeting
Austin, Texas (April 18, 2016) - Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism and cancer, today announced that it will present in a scientific poster session at the Annual Meeting of the American Association for Cancer Research (AACR) being held April 16-20, 2016 in New Orleans, Louisiana.
Poster Presentation Details:
Abstract Title (#1042): Development of AEB1102, an engineered human arginase 1 for patients with solid tumors
| • | Presentation Date and Time: Monday, April 18 from 8:00 a.m. – 12:00 p.m. CT |
| • | Session: Metabolic Reprogramming in Cancer |
| • | Location: Morial Convention Center, Exhibit Halls G-J |
About Aeglea BioTherapeutics
Aeglea is a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism and cancer. The company’s engineered human enzymes are designed to degrade specific amino acids in the blood in order to reduce toxic levels of amino acids in inborn errors of metabolism or to exploit the dependence of certain cancers on specific amino acids.
# # #
Media Contacts:
Ina McGuinness
BrewLife
805.427.1372
imcguinness@brewlife.com